Health |Pfizer’s TUKYSA Regimen
Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
October 7, 2026 · 12:57 PM · NEW YORK
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. The approval expands the use of TUKYSA to frontline, an earlier stage of metastatic disease, offering a new chemotherapy-free maintenance treatment option that may help further delay disease progression.
- PublishedOctober 7, 2026 · 12:57 PM
- LocationNEW YORK
- IndustryHealth
- LanguageEN
Published by Business Wire. Read the original announcement for the full release.
Read the full announcement →